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IBD LIVE
Development of the IBD Disk: A Visual Self-administered Tool for
Assessing Disability in Inﬂammatory Bowel Diseases
Subrata Ghosh, MD,1 Edouard Louis, MD,2 Laurent Beaugerie, MD, PhD,3 Peter Bossuyt, MD,4
Guillaume Bouguen, MD, PhD,5 Arnaud Bourreille, MD, PhD,6 Marc Ferrante, PhD,7
Denis Franchimont, MD, PhD,8 Karen Frost, MN-NP,9 Xavier Hebuterne, MD, PhD,10,11
John K. Marshall, MD,12 Ciara O’Shea, PhD,13 Greg Rosenfeld, MD,14 Chadwick Williams, MD,15
and Laurent Peyrin-Biroulet, MD16
Background: The Inﬂammatory bowel disease (IBD) Disability Index is a validated tool that evaluates functional status; however, it is used mainly in
the clinical trial setting. We describe the use of an iterative Delphi consensus process to develop the IBD Disk—a shortened, self-administered adaption
of the validated IBD Disability Index—to give immediate visual representation of patient-reported IBD-related disability.
Methods: In the preparatory phase, the IBD CONNECT group (30 health care professionals) ranked IBD Disability Index items in the perceived order of
importance. The Steering Committee then selected 10 items from the IBD Disability Index to take forward for inclusion in the IBD Disk. In the consensus
phase, the items were reﬁned and agreed by the IBD Disk Working Group (14 gastroenterologists) using an online iterative Delphi consensus process.
Members could also suggest new element(s) or recommend changes to included elements. The ﬁnal items for the IBD Disk were agreed in February 2016.
Results: After 4 rounds of voting, the following 10 items were agreed for inclusion in the IBD Disk: abdominal pain, body image, education and work,
emotions, energy, interpersonal interactions, joint pain, regulating defecation, sexual functions, and sleep. All elements, except sexual functions, were
included in the validated IBD Disability Index.
Conclusions: The IBD Disk has the potential to be a valuable tool for use at a clinical visit. It can facilitate assessment of inﬂammatory bowel disease-
related disability relevant to both patients and physicians, discussion on speciﬁc disability-related issues, and tracking changes in disease burden over time.
(Inﬂamm Bowel Dis 2017;23:333–340)
Key Words: IBD disability index, disability, quality of life, patient outcome assessment, severity of illness index
I nﬂammatory bowel disease (IBD) has a substantial and multi-faceted burden, characterized by distressing and debilitating
symptoms that can restrict the affected patient’s freedom,
diminish their physical and psychological well-being, reduce
productivity, and isolate them socially.1–9 A recent survey per-
formed by the European Federation of Crohn’s and Ulcerative
Colitis Associations and involving 4670 patients with IBD found
that 67% of respondents frequently considered the availability of
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toilets when planning to attend an event, 60% felt stressed or
pressured about taking sick leave from work due to IBD, 56%
felt that IBD had affected their career path, and 35% felt that IBD
had prevented them from pursuing an intimate relationship.1
Addressing and improving the cumulative burden of
disease, returning to a “normal life,” and preventing disability
are now major therapeutic goals in IBD.10 Because of this, it is
increasingly important to monitor aspects of functioning and dis-
ability in the patient with IBD in addition to assessing the clinical
and inﬂammatory manifestations of the disease.10–12 The IBD
Disability Index (IBD-DI) is a physician-administered tool that
evaluates the functional status of patients with IBD.13–15 The
IBD-DI was developed using a formal consensus process16 that
integrated evidence from preparatory studies and expert opinion
based on categories from the World Health Organization Interna-
tional Classiﬁcation of Functioning, Disability and Health
(ICF).17 Participants involved in the consensus process provided
a balanced representation of all relevant health professions and all
World Health Organization-designated world regions. The IBD-
DI has recently been validated for use in clinical trials and
epidemiological studies and shows high internal consistency,
interobserver reliability, and construct validity, with moderate
intraobserver reliability.15
While the IBD-DI provides a robust means of assessing
IBD-related disability, it needs to be administered by a health care
professional and is mainly for use in the clinical trial setting. We
propose that a shortened, patient-friendly adaption of the IBD-DI,
comprising items that have undergone rigorous validation, would
be useful for monitoring disability in the IBD outpatient. In order
for the tool to stimulate meaningful patient–physician dialogue, it
needs to focus on items that are useful to both the patient and the
physician.
The development of self-administered versions of disease
monitoring instruments is becoming an area of interest in the
outpatient setting, potentially allowing remote monitoring of
health.18 As an example, a 10-item visual instrument, known as
the Psodisk, has been developed and validated in patients with
psoriasis.19–21 The Psodisk is a patient-reported outcome measure
that includes items relevant to disability and provides the physi-
cian and patient with an immediate and intuitive visual represen-
tation of the disease burden for that individual. Changes in disease
burden over time can also be assessed if the Psodisk is used
regularly.
In this article, we describe the use of an iterative Delphi
consensus process to develop the IBD Disk—a self-administered
and shortened adaption of the validated IBD-DI. The IBD Disk
application is based on the Psodisk platform and can be used in
the outpatient setting to give immediate visual representation of
patient-reported IBD-related disability.
MATERIALS AND METHODS
The methodology for developing the IBD Disk is shown in
Figure 1. The development of the IBD Disk was initially an effort
FIGURE 1. Flow chart of the consensus process.
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of IBD CONNECT, an international educational program de-
signed to provide training and tools (including essential motiva-
tional interviewing techniques) to improve collaboration and
communication between health care professionals and their
patients with IBD (see Acknowledgement). In the preparatory
phase of the process, the IBD CONNECT Steering Committee
(S.G., E.L., L.P-B.) proposed that the elements for the IBD Disk
be based on the validated IBD-DI.13 To ensure that the tool would
be useful in the outpatient setting, it was decided to limit
the number of items included to 10. Participants in an IBD
CONNECT meeting (30 global gastroenterologists and nurses;
Prague, Czech Republic; May 11–12, 2012) then completed a
paper-based survey that ranked the IBD-DI items in order of
importance (i.e., relevance to both the patient and physician)
and collected general feedback on which items should be included
in the IBD Disk. The Steering Committee reviewed feedback and
selected 10 draft items by consensus from the IBD-DI, with
accompanying descriptive statements, for the IBD Disk.
Between August 2015 and February 2016, the IBD Disk
Working Group (comprised of 14 gastroenterologists from
Belgium, Canada, and France) used an iterative Delphi process
to reﬁne and agree to the IBD Disk items proposed by the IBD
CONNECT program. Communication was solely through an
online platform. The Working Group members were asked to
rank each of the selected items from the IBD-DI in the order of
importance. In addition, a free text space allowed members to
suggest new element(s) (including those not in the IBD-DI) or
recommend changes to/deletions of included elements. The level
of agreement for new suggestions was determined in the
subsequent voting round; suggestions meeting 75% or more
agreement were accepted. After each round of feedback, the
modiﬁed proposal was recirculated. The ﬁnal items for the IBD
Disk were agreed in February 2016.
RESULTS
Preparatory Phase
Participants in the IBD CONNECT meeting ranked 19
IBD-DI items in the perceived order of importance (Table 1).
“General health,” “abdominal pain,” and “energy” were the 3
items ranked as most important, whereas “abdominal pain,”
“energy,” and “regulating defecation” were the items selected
most frequently.
Based on the feedback given, the Steering Committee
proposed 10 draft items with accompanying descriptive state-
ments for the IBD Disk (Table 1). Given the similarity and
overlap of some items, it was decided to group some elements
together (e.g., difﬁculty with school or studying activities and
difﬁculty with work or household activities under the heading
of “education and work”; feeling sad, low, or depressed and
feeling worried or anxious under the heading of “emotions”;
and difﬁculty with a personal relationship and difﬁculty par-
ticipating in the community under the heading of “interpersonal
interactions”). It was also agreed to include “sexual functions”
from the comprehensive ICF core set.
Consensus Phase
The 14 Working Group members completed 4 rounds of
voting to achieve consensus on elements to include in the IBD
Disk.
Round 1
“Emotions and work” was ranked as the most important,
followed by “regulating defecation.” “Sexual functions” was con-
sidered the least important. The only new suggestion was to
include “pain in joints” as an additional item, taken from the
IBD-DI and the comprehensive ICF core set.
Round 2
“Emotions and work” and “regulating defecation” remained
the most important items and “pain in joints” was the least impor-
tant. Two suggestions were made: ﬁrst, “sexual functions” should
be removed as it is not included in the validated IBD-DI, and
second, “sleep” and “energy” should be combined as they are
included as a single item in the validated IBD-DI. No new ele-
ments were proposed.
Round 3
Participants voted to retain “sexual functions” as an item
and to retain “sleep” and “energy” as separate items. It was sug-
gested that “general health” be removed. No new elements were
proposed.
Round 4
It was agreed to remove “general health” from the IBD
Disk. No new elements were proposed.
The ﬁnal IBD Disk included 10 items (Table 1). The tool
comprises a questionnaire with an explanatory statement for each
of the items, which should be scored on a disc-shaped visual
analog scale from 0 (absolutely disagree) to 10 (absolutely agree)
(Fig. 2). All included elements, except “sexual functions,” were
included in the validated IBD-DI. “Sexual functions” is included
from the comprehensive ICF core set.
DISCUSSION
One of the major therapeutic goals in IBD clinical practice
is to prevent disability and to minimize disruption to the
patient’s education, work, family, and social life. This goal re-
quires long-term collaboration between a patient and their gas-
troenterology team. Indeed, studies have shown that patient
satisfaction with health care is largely inﬂuenced by their inter-
actions with health care professionals,22–26 with suggestion that
improved patient engagement leads to improved treatment
adherence and outcomes.27–31
However, there is often a discrepancy between the per-
spective of the health care professional and the patient. Health
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care professionals may underestimate the impact that IBD has on
the patient’s daily life,32 or they may misinterpret what matters
most to patients about their disease.33 As indicated by the
European Federation of Crohn’s and Ulcerative Colitis Associa-
tions survey, patients often have difﬁculty in expressing their
needs to their health care professional or are not asked probing
TABLE 1. Selection of Items for Inclusion on the IBD Disk
Importance of IBD-DI Items as Perceived by
IBD CONNECT Training Meeting Participants
(n ¼ 30)a
Items Selected by IBD CONNECT Steering
Committee for Inclusion in First Consensus
Voting Roundb
Final Items for Inclusion on IBD Disk, as Agreed
by IBD Disk Working Group Using Iterative
Delphi Processc
General health (1) General health
Abdominal pain: aches or pains in your
stomach or abdomen (2)
Abdominal pain: aches or pains in stomach or
abdomen
Abdominal pain: aches or pains in stomach or
abdomen
Energy: not feeling refreshed during the day,
feeling tired, little energy (3)
Energy: not feeling rested and refreshed during
the day, and feeling tired and without energy
Energy: not feeling rested and refreshed during
the day, and feeling tired and without energy
Regulating defecation: difﬁculty coordinating/
managing defecation, including getting to
a toilet and cleaning oneself afterward (4)
Regulating defecation: difﬁculty coordinating
and managing defecation, including getting
to a toilet and cleaning afterward
Regulating defecation: difﬁculty coordinating and
managing defecation, including choosing and
getting to an appropriate place for defecation
and cleaning afterward
Emotions: feeling sad, low, or depressed (5) Emotions: feeling sad, low or depressed, and/or
worried or anxious
Emotions: feeling sad, low, or depressed, and/or
worried or anxiousEmotions: feeling worried or anxious (10)
Immediate family members: affect your
problems and difﬁculties (6)
Interpersonal interactions: difﬁculty with personal
relationships and/or difﬁculty participating in
the community
Interpersonal interactions: difﬁculty with personal
relationships and/or difﬁculty participating in
the communityInterpersonal interactions: difﬁculty with
a personal relationship (9)
Interpersonal interactions: difﬁculty
participating in the community (13)
Work: difﬁculty with work or household
activities (7)
Education and work: difﬁculty with school or
studying activities, and/or difﬁculty with
work or household activities
Education and work: difﬁculty with school or
studying activities, and/or difﬁculty with work
or household activitiesEducation: difﬁculty with school or studying
activities (16)
Sleep: difﬁculty sleeping, such as falling asleep,
waking up frequently during the night, or
waking up too early in the morning (8)
Sleep: difﬁculty sleeping, such as falling asleep,
waking up frequently during the night or
waking up too early in the morning
Sleep: difﬁculty sleeping, such as falling asleep,
waking up frequently during the night or
waking up too early in the morning
Body image: problem with the way your body
or body parts look (11)
Body image: not liking the way body or body
parts look
Body image: not liking the way body or body
parts look
Digestive functions: feel you have lost weight
in the last week (12)
Looking after one’s health: difﬁculty looking
after oneself, including maintaining
a balanced diet (14)
Health services: receive health care needed (15)
Medication: affects your problems and
difﬁculties (17)
Health professionals: affects your problems and
difﬁculties (18)
Social security: beneﬁt from support from
social security system (19)
Arthritis or arthralgia present (not ranked) Joint pain: pains in the joints of your body
Sexual functions: difﬁculty with the mental
and/or physical aspects of sex
Sexual functions: difﬁculty with the mental and/
or physical aspects of sex
All elements (except “sexual functions”) were included in the IBD-DI.13
aNumber in parentheses after each item indicates importance rank; the presence of arthritis or arthralgia was not included in the ranking because although this information is recorded in
the IBD-DI,13 it is not one of the 19 IBD-DI questions.
bAll elements (except “general health”) were taken from the World Health Organization ICF comprehensive code set for IBD17; all elements (except “sexual functions”) were included in
the IBD-DI.13
cAll elements were taken from the World Health Organization comprehensive ICF core set for IBD.17
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questions that reveal the true impact of their disease.1 Part of this
disconnect may be attributed to the lack of suitable or accessible
tools with which to illicit and monitor key markers of disease
burden or disability in outpatients with IBD.34
The IBD-DI is a physician-administered tool that captures
speciﬁc objective items that describe what it means to live with
IBD.13 The published version of the questionnaire comprises 28
items: 18 items that cover different aspects of disability across the
3 domains of body functions, body structures, and activities and
participation; 8 supplemental items that provide information about
how the patient’s environment interacts with their disease; and 2
items relating to social security and access to the health care
system.13 These items were rigorously generated through a com-
prehensive process involving patient concept elicitation inter-
views, expert interviews, item generation, content validity,
patient cognitive interviews, and a quantitative study. A modiﬁed
version of the IBD-DI comprising 14 disability-related questions
(general health, sleep, energy, emotions [feeling sad/depressed
and feeling worried/anxious], body image, abdominal pain,
regulating defecation, looking after one’s health, interpersonal
activities [difﬁculty with personal relationships/difﬁculty with
community participation], work, education, and number of liquid/
very soft stools) was recently rigorously validated in an indepen-
dent population-based cohort of patients with IBD in France.15
The IBD Disk was developed using a consensus-based
process to select elements from the IBD-DI that are most likely to
be important in assessing a patient’s disease burden and had rel-
evance to both the patient and physician. Several items (difﬁcul-
ties with work/education and feeling depressed/anxious) were
combined owing to similarities in concept. In addition, the IBD
CONNECT Steering Committee suggested inclusion of “sexual
functions” from the ICF comprehensive core set.17 Sexual dys-
function is a common concern in patients with IBD and may be
present in approximately half of women and a quarter of men with
IBD.35 Based on clinical experience, the Steering Committee con-
sidered that sexual dysfunction was likely to be important to
patients and may not have been captured in the development of
the IBD-DI because patients felt uncomfortable discussing the
topic in the preparatory discussions. The Working Group agreed
to include this item. The Working Group later also agreed to
include “joint pain,” from the IBD-DI and ICF core set. Articular
involvement is the most common extraintestinal manifestation in
IBD, even in patients who are in clinical and endoscopic IBD
remission. A recent Swiss cohort study found 44% of patients
with IBD have inﬂammatory articular disease.36 The Working
Group considered that it was important to include “joint pain”
in the IBD Disk, as patients do not always attribute this to IBD
and it may be a relevant point for discussion in a clinical consul-
tation. In the last round of voting, “General health” was excluded
from the IBD Disk, as the wide range of speciﬁc items now
included in the disk covered the key elements of disability asso-
ciated with IBD. The Working Group also felt that keeping the
number of items to 10 would facilitate the use of the tool in
clinical practice.
The resulting IBD Disk questionnaire and scoring disk (Fig.
2) ﬁt on a single page that would be easy to translate and admin-
ister to patients before or during a clinic visit. A hypothetical
example of how a patient’s IBD Disk assessment provides a visual
representation of disease burden and may change over time with
good disease management is shown in Figure 3.
The IBD Disk could be used to track changes in disease
burden over time, assess and monitor treatment efﬁcacy in terms
of disease burden, and set short-term and long-term goals. Regular
completion of the IBD Disk, together with regular clinical
FIGURE 2. The IBD Disk questionnaire and scoring disk.
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assessments during clinic visits may provide a more complete
picture of the patient’s overall health, well-being, and disease
state. Short-term goals that include reducing the IBD Disk scores
for all or selected elements could be set and monitored over time,
and treatment modiﬁed as required if goals are not reached. Ex-
planations for changes in any speciﬁc element may be explored
further at the clinic. Monitoring to achieve longer term goals of
keeping IBD Disk scores low could provide information on the
efﬁcacy of and adherence to maintenance treatment. It will also be
a good tool for a patient-centered conversation at follow-up visits.
This use of visual feedback to allow patients to see changes
in their disease status may create a new experience for the patient
and translate into potential improvements in understanding,
behavior and treatment adherence. Furthermore, inclusion of
items that are of relevance to both the patient and health care
professional should allow meaningful dialogue between the 2
parties. This can be helpful for goal setting and shared decision
making in a chronic condition such as IBD, which should be
based on participatory medicine, mutual respect, patient engage-
ment, and communication.
Interestingly and somewhat surprisingly, there is currently
a lack of evidence in the literature evaluating how visual
representation of disease state may impact patient outcomes. Further
work should include assessment of changes in health behaviors in
patients who measure their IBD burden with the IBD Disk.
It must be acknowledged that one of the possible short-
comings of this tool is the lack of direct patient involvement in
selection of the items for inclusion. Nevertheless, items were
obtained from the IBD-DI and ICF core set, which were
developed based on analysis of a qualitative study (6 focus
groups with 26 participants) to identify aspects of the “lived
experience” of IBD and a multicenter cross-sectional study to
describe functioning and health of persons with IBD. This gives
us conﬁdence that the components of the IBD Disk are meaning-
ful to patients.
The next step for the IBD Disk will be to evaluate its
operating characteristics in clinical practice as an outpatient tool
in comparison to the IBD-DI, followed by validation of the
capacity of the IBD Disk to assess changes in disability. As
a potential value of the IBD Disk lies in the long-term monitoring
of IBD-associated disability, some longitudinal studies will be
needed. Studies that directly compare the IBD Disk and the IBD-
DI—and other clinical and nonclinical measures—will also be
useful.
In conclusion, the IBD Disk is a self-administered adaption
of the validated IBD-DI that has the potential to be a valuable tool
for assessing IBD-related disability experienced by the patient and
promoting discussion on speciﬁc issues important to the patient
and the health care professional during consultation.
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